NCT03357627 is a Phase 1 clinical trial of TAK-659 in Lymphoma, Non-Hodgkin, sponsored by Calithera Biosciences, Inc.

Who is sponsoring NCT03357627?

NCT03357627 is sponsored by Calithera Biosciences, Inc.

What drugs are being tested in NCT03357627?

Interventions in NCT03357627: TAK-659, Venetoclax.

What condition does NCT03357627 study?

NCT03357627 studies Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular.

Is NCT03357627 still recruiting?

NCT03357627 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT03357627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Completed Phase 1 Last updated 8 February 2023

What this trial tests

Phase 1 trial testing TAK-659 in Lymphoma, Non-Hodgkin in 43 participants. Completed in 3 August 2021.

Timeline

16 February 2018

Primary endpoint
3 August 2021

3 August 2021

Quick facts

Lead sponsor	Calithera Biosciences, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	other
Enrollment	43
Start date	16 February 2018
Primary completion	3 August 2021
Estimated completion	3 August 2021
Sites	15 locations across Canada, United States, Germany

Drugs / interventions tested

TAK-659 — full drug profile →
Venetoclax (venetoclax) — full drug profile →

Conditions studied

Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Lymphoma, Large B-cell, Diffuse — all drugs for Lymphoma, Large B-cell, Diffuse →
Lymphoma, Follicular — all drugs for Lymphoma, Follicular →

Sponsor

Calithera Biosciences, Inc — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin or Lymphoma, Large B-cell, Diffuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1 prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when administered in combination.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

BCL-2 as therapeutic target for hematological malignancies.
Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, et al · · 2018 · cited 153× · PMID 29747654 · DOI 10.1186/s13045-018-0608-2
Targeting the Bcl-2 Family in B Cell Lymphoma.
Adams CM, Clark-Garvey S, Porcu P, Eischen CM. · · 2018 · cited 112× · PMID 30671383 · DOI 10.3389/fonc.2018.00636
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
Leverson JD, Cojocari D. · · 2018 · cited 31× · PMID 30406027 · DOI 10.3389/fonc.2018.00458
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas.
Minson A, Tam C, Dickinson M, Seymour JF. · · 2022 · cited 4× · PMID 35267584 · DOI 10.3390/cancers14051276
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD, Horwitz SM. · · 2021 · cited 4× · PMID 33906725 · DOI 10.1053/j.seminhematol.2021.02.004

Verify or expand the search:

Other trials of TAK-659

Trials testing the same drug.

NCT04079738 — Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib · Phase 1, PHASE2 · terminated
NCT03772288 — A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) · Phase 1 · withdrawn
NCT03338881 — A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participa · Phase 1 · withdrawn
NCT03359733 — A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor · Phase 1 · withdrawn
NCT03123393 — TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Phase 2 · terminated

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting

Other Calithera Biosciences, Inc trials

Trials by the same sponsor.

NCT05319028 — Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Phase 2 · terminated
NCT04698681 — NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial · terminated
NCT04607512 — Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects · Phase 1 · completed
NCT04540965 — Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects · Phase 1 · completed
NCT04265534 — KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamo · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03357627 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Calithera Biosciences, Inc
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03357627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing